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Abstract 
Purpose: To search for novel biomarkers for early diagnosis of cervical cancer, as well as novel 
therapeutic target for cervical cancer. 
Methods: A total of 96 cervical tissue specimens were collected from patients in the Second Affiliated 
Hospital of Zhengzhou University, out of which 10 were normal control. The remaining specimens (86) 
were cervical cancer specimens and were divided into 4 groups (A - D) based on tumor-biomarker 
levels of CA125 and SCC. Quantitative real-time polymerase chain reaction technology (qRT-PCR) was 
used to detect the expressions of miRNA-143, miRNA-34A, miRNA-944, miRNA-101 and miRNA-218 in 
the cervical cancer tissues. 
Results: The levels of CA125 (U/mL) and SCC (ug/L) expressed in normal control group and groups A - 
D were 11.75 and 0.73 (n = 10), 382 and 2.72 (n = 25), 912.9 and 3.93 (n = 21), 1675 and 5.87 (n = 29), 
and 2120 and 6.66 (n = 11), respectively. Furthermore, qRT-PCR results showed that the expressions 
of miRNA-944 and miRNA-218 in cervical cancer tissues were markedly up-regulated compared to 
normal control tissues (p < 0.01). In contrast, the expression level of miRNA-143, miRNA-34A, and 
miRNA-101 were significantly decreased (p < 0.01).  
Conclusion: The biomarkers, miRNA-143, miRNA-34A, miRNA-944, miRNA-101 and miRNA-218, can 
be considered novel for early diagnosis of cervical cancer.   
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Cervical cancer is a serious threat to the health 
of women, and is one of the leading causes of 
cancer-related death in the world due to delayed 
diagnosis and high risk of metastasis [1]. 
Furthermore, 85 % of the cervical cancers occur 
in developing countries, such as China and India 
[2]. Currently, chemotherapy is the commonly 
used strategy to prevent the relapse and 
metastasis of cervical cancer besides surgery [3]. 
However, early diagnosis is the most important 
strategy for treating cervical cancer [4]. 
 
MicroRNAs (miRNAs) are a class of non-coding 
RNAs (21 - 24 nucleotides in length) that are 
critical for many important processes such as 
development, differentiation and even 
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carcinogenesis, and can regulate the chemo 
sensitivity of tumor cells [5,6]. Accumulating 
evidence has demonstrated that dysregulation of 
miRNAs which function as tumor promoter or 
suppressor depending on the nature of its 
targets, occurs in various human cancers [7].  
 
Currently, miRNAs involved in carcinogenesis 
and progression of cervical cancer have been 
widely investigated [8]. In our present study, we 
investigated the expressions of miRNA-143, 
miRNA-34A, miRNA-944, miRNA-101 and 
miRNA-218 in cervical cancer tissues, and 
explored their regulative significance on cervical 
cancer tissues. Our research on miRNAs is 
aimed to provide reference for the early clinical 
diagnosis of cervical cancer and provide novel 




Subjects and sample collection 
 
A total of 86 fresh cervical tissue specimens 
were obtained from patients treated in the 
Second Affiliated Hospital of Zhengzhou 
University for squamous cell carcinoma. 
Additionally, normal cervical tissue specimens 
(group A) were also obtained from patients 
without cervical cancer (n = 10). The 86 cervical 
cancer patients were divided into 4 groups (B - 
E) based on the tumor-biomarker levels of 
CA125 and SCC, and the numbers of subjects 
were 25, 21, 29 and 10, respectively. All the 
patients enrolled were required to read and sign 
an informed consent form voluntarily before 
enrollment. All the experimental designs were 
carried out in accordance with the declaration of 
Helsinki promulgated in 1964 as amended in 
1996 [9] and approved by the Ethics Committee 
of the Second Affiliated Hospital of Zhengzhou 
University (Ethical approval No.: S2013-06-23).   
 
RNA extraction and reverse transcription 
 
Total RNA was extracted from each of the 
experimental groups using Trizol Reagent 
(Shanghai Sangon, Shanghai, China) according 
to the manufacturer's instructions. Reverse 
transcription (RT) was performed on RNA 
samples, followed by polymerase chain reaction 
(PCR) amplification.  
 
Quantitative real-time polymerase chain 
reaction (qRT-PCR) 
 
Quantitative RT-PCR was performed to detect 
the relative transcript levels of miRNA-143, 
miRNA-34A, miRNA-944, miRNA-101 and 
miRNA-218, respectively. PCR was performed 
under the following conditions: 94 °C for 4 min 
followed by 40 cycles of 94 °C for 1 min, 56 °C 
for 1 min and 72 °C for 1 min. U6 snRNA was 
used as an endogenous control to normalize the 
expression of miRNA-143, miRNA-34A, miRNA-
944, miRNA-101 and miRNA-218, respectively. 
qRT-PCR was performed using FastStart 
Universal SYBR Green Master kit (Roche 
Diagnostics) and analyzed with an Applied 
Biosystems 7900 Real-Time PCR System. The 
specific primer pairs (Invitrogen, Shanghai, 




All the data are presented as mean ± standard 
deviation (SD) and group comparison was 
performed by ANOVA (SPSS 16.0). P < 0.05 




Clinicopathologic characteristics of subjects 
 
Ten normal women and eighty six women with 
cervical cancer were included in the study. 
 
Table 1: Primers used for quantitative real-time PCR 
 
   
U6 F 5’GCTTCGGCAGCACATATACTAAAAT3’ 
 R 5’CGCTTCACGAATTTGCGTGTCAT3’ 
miRNA-143 F GGGCGGGTGCAGTGCT 
 R GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACACCAGA 
miRNA-34A F GGGCGGTGGCAGTGTCTT 
 R GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACACAACC 
miRNA-944 F GGGCGGAAATTATTGTA 
 R GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACCTCATCC 
miRNA-101 F GGGCGGCAGTTATCACAG 
 R GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACAGCATC 
miRNA-218 F GGGCGGTTGTGCTTGAT 
 R GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACATGGT 
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Basic characteristics of five groups are given in 
Table 2. A represented normal control, and B-E 
represented the 4 groups of cervical cancer 
patients divided according to the biomarker 
expression levels of cancer antigen 125 (CA125) 
and squamous cell carcinoma antigen (SCC). 
Overall, no obvious difference was observed for 
the height, age, weight, and fasting blood-
glucose (FBG) in the five groups (p > 0.05). 
However, the values of CA125 and SCC in the 5 
groups were significantly different. As shown in 
Table 2, the CA125 and SCC values of the 4 
groups of patients with cervical cancer were 





To further validate the altered expressions of 
miRNA-143, miRNA-34A, miRNA-944, miRNA-
101 and miRNA-218 in cervical cancer, we 
tested the expressions of miRNA-143, miRNA-
34A, miRNA-944, miRNA-101 and miRNA-218 in 
the cervical cancer tissues and normal tissues by 
using qRT-PCR assay. The amplification plots of 
qRT-PCR are shown in Figure 1. As shown in 
Table 3, miRNA-944 and miRNA-218 in the 4 
groups of cervical cancer tissues were found to 
be expressed at significantly higher levels when 
compared to the normal control tissues (p < 
0.01). Meanwhile, the expression levels of 
miRNA-143, miRNA-34A, and miRNA-101 in the 
4 groups of patients with cervical cancer were 
relatively down-regulated (p < 0.01). The results 
showed that the expressions of miRNA-944 and 
miRNA-218 changed dramatically with the 
serious extent of cervical cancer. 
 
 
Table 2: Baseline demographics and disease characteristics 
 
Group Height (cm) Age Weight FBG (mmol/L) CA125 (U/mL) SCC (ug/L) 
A 159.91±4.65 43.62±10.33 53.41±4.17 5.04±1.25 11.75±2.98 0.73±0.28 
B 162.76±4.54 41.16±9.12 55.04±6.19 4.94±0.64 382±97.29 2.72±0.88 
C 162.76±3.97 41.16±8.44 55.04±6.13 4.9412±0.93 912.9±99.76 3.93±0.93 
D 162.03±4.73 42.03±8.26 58.72±5.07 4.69±0.89 1675±246.78 5.87±1.14 
E 160.82±5.40 43.09±9.28 53.91±4.83 4.61±0.89 2120±234.45 6.66±1.28 
Key: FBG: Fasting blood-glucose; A: normal control; B-E represented the 4 groups of cervical cancer patients, 
and cervical cancer patients were divided according to the biomarkers expression levels of CA125 and SCC 
 
 
Figure 1: The amplification plots of real-time quantitative PCR. 
 
Wang et al 
Trop J Pharm Res, July 2016; 15(7): 1390  
 
    Table 3: Expressions of the miRNA-143, 34A, 944, 101 and 218 in patients with cervical cancer 
  
 miRNA-143 miRNA-34A miRNA-944 
A 0.744863±0.156102 0.725107±0.194532 0.695712±0.190653 
B 0.000413±0.000113 ** 0.092564±0.012031 ** 25.22961±5.987026 ** 
C 0.000384±0.000124 ** 0.087595±0.019765 ** 27.50011±5.976513 ** 
D 0.000343±0.000123 ** 0.065139±0.015563 ** 32.41054±11.74653 ** 
E 0.000341±0.000115 ** 0.063897±0.021022 ** 39.55085±12.65385 ** 
    
 miRNA-101 miRNA-218  
A 1.265348±0.344745  0.732692±0.243097     
B 0.373367±0.098217 ** 21.18917±2.687207 **  
C 0.398324±0.176539 ** 24.84102±5.210923 **  
D 0.448022±0.138603 ** 25.87216±7.864375 **  
E 0.546068±0.176068 ** 35.21287±7.412874 **  
A: normal control; B-E represented the 4 groups of cervical cancer patients, and cervical cancer patients were 
divided according to the biomarkers expression levels of CA125 and SCC; ** significant difference at p < 0.01, 




In the present study, we systematically 
investigated the expression of miRNA-143, 
miRNA-34A, miRNA-944, miRNA-101 and 
miRNA-218 in cervical cancer tissues, and found 
that in cervical cancer tissues, miRNA-944 and 
miRNA-218 were dramatically up-regulated, 
whereas miRNA-143, miRNA-34A and miRNA-
101 were decreased. 
 
A number of studies have identified miRNA-143 
as a tumor suppressor gene lost expression 
significantly in several cancer types, including 
breast and cervical cancers [10-13], which is 
consistent with our results on the expression of 
miRNA-143 in cervical cancer tissues. miRNA-
143 was expressed at significantly lower levels 
when compared to the normal control tissues. In 
addition, miRNA-34A belongs to the miRNA-34 
family and acts as a tumor suppressor in several 
cancer types, and ectopic miRNA-34 expression 
induces apoptosis, cell-cycle arrest or 
senescence [14,15]. Recently, many studies 
have reported that miRNA-34A was down-
regulated in many human cancers through 
hypermethylation of promoter DNA to silence this 
miRNA [14,16]. In the present study, miRNA-34A 
in patients with cervical cancer was also down-
regulated.  
 
The gene coding for miRNA-944 is located in the 
intron of TP63 gene, which encodes tumor 
protein 63 (p63). And the expression of miRNA-
944 may correlate with TP63 expression [17]. 
miRNA-944, which targets an mRNA of SOCS 
(suppressor of cytokine signaling) family tumor 
suppressor genes, can promote tumor growth, 
proliferation, and squamous differentiation [18]. 
In addition, miRNA-944 was first identified in 
human cervical cells using a small RNA cloning 
approach and it was reported that it is 
significantly more abundant in cervical cancer 
tissues than their normal counterparts [18,19]. In 
the present study, the expression of miRNA-944 
in cervical cancer tissues had significantly 
changed compared to other miRNAs and 
miRNA-944 was expressed at significantly higher 
levels compared to normal tissues. Thus, the 
miRNA-944 in cervical cancer tissues might be 
regarded as an important biomarker in the 
process of diagnosing cervical cancer.  
 
miRNA-101 is one of the down-regulated 
miRNAs in a diverse of malignancies relative to 
their non-tumor counterparts, such as colorectal 
cancer, ovarian carcinoma, and non-small cell 
lung cancer, etc [20-22]. Furthermore, down-
regulated expression of miRNA-101 might be 
involved in the progression of malignant cancers 
[23]. The results show that the expression of 
miRNA-101 in patients with cervical cancer is 
down-regulated when compared with the normal 
tissues. As a broadly conserved miRNA, miR-
218 is considered a tumor suppressor in multiple 
carcinomas by targeting different genes, such as 
bladder cancer, liver cancer, and breast cancer, 
etc [24-26].  
 
Many researchers have reported that the 
expression of miRNA-218 was down-regulated in 
various human tumor cells and tissues. However, 
miRNA-218 expression was up-regulated in 
cervical cancer tissues. The results demonstrate 
that miRNA-944 and miRNA-218 significantly 
increase in cervical cancer tissues. On the 
contrary, miRNA-143, miRNA-34A, and miRNA-
101 in cervical cancer tissues are down-
regulated. 
 
Wang et al 




The findings of the present work indicate that the 
expressions of miRNA-143, miRNA-34A, miRNA-
944, miRNA-101 and miRNA-218 in cervical 
cancer tissues are different from those of normal 
tissues. Thus, these miRNAs are suitable as 
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